Vanguard Portfolio Management
BIO icon

Vanguard Portfolio Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Vanguard Portfolio Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$240M Sell
816,198
-12,988
-2% -$3.68M 0.01% 1114
2026
Q1 		$231M Buy
+829,186
New +$239M 0.01% 1050

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management's BIO Position: Q2 2026 in Review

Vanguard Portfolio Management reduced its Bio-Rad Laboratories Class A (BIO) stake by 1.6% in Q2 2026, selling an estimated $3.68M and leaving 816,198 shares worth $240M. The position accounts for 0.01% of the portfolio, ranked #1114.

Vanguard Portfolio Management first reported a position in BIO in Q1 2026 and has held it in 2 quarters since. 391 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Vanguard Portfolio Management held 816,198 shares of Bio-Rad Laboratories Class A worth $240M as of Q2 2026.
  • Vanguard Portfolio Management sold 12,988 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $3.68M.
  • Bio-Rad Laboratories Class A made up 0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #1114 holding.
  • Vanguard Portfolio Management first reported a position in Bio-Rad Laboratories Class A in Q1 2026 and has held it in 2 quarters since.
  • 391 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.